Auro-Abacavir/Lamivudine 600/300 mg TABLETS
PDF Leaflet Revision Date: 25 September 2018
Clinical Summary
Quick overview from the medicine insert
Indication
For treatment of HIV in adults and adolescents from 12 years.
Dosage (summary)
One tablet once daily; not for patients <40 kg.
Onset of Action / Duration
Onset: 11 days, Duration: variable
Special Populations
- Hepatic impairment
- Renal impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding; teratogenicity observed.
Key Drug Interactions
- Zalcitabine may inhibit lamivudine phosphorylation
- Trimethoprim increases lamivudine exposure
Contraindications
- Hypersensitivity to abacavir or lamivudine
- Moderate to severe hepatic impairment
- Pregnancy and breastfeeding
- Renal impairment (creatinine clearance < 50 mL/min)
- Weight < 40 kg
- Children < 12 years
Common side effects
- Hypersensitivity reactions
- Nausea
- Vomiting
- Diarrhea
- Rash
Counselling Points
- Inform about hypersensitivity risks
- Do not restart after hypersensitivity reaction
- Monitor for signs of lactic acidosis
- Regular follow-up for opportunistic infections
Serious warnings
- Risk of fatal hypersensitivity reactions
- Lactic acidosis
- Severe hepatomegaly
- Immune Reconstitution Inflammatory Syndrome (IRIS)
Important Disclaimer
The Auro-Abacavir/Lamivudine 600/300 mg TABLETS professional information leaflet below is the property of Aurobindo Pharma and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
